Accelerating biologics development
Abstract: This report provides a roadmap for assessing and selecting the right partner to get promising biological therapies to patients quickly. Criteria includes:
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
Entries by Thomas Gabrielczyk
Accelerating biologics development
Abstract: This report provides a roadmap for assessing and selecting the right partner to get promising biological therapies to patients quickly. Criteria includes:
Sino Biological Newly Launched A Panel of Research Reagents for SARS-CoV-2 Omicron Variant (B.1.1.529)
Sino Biological, Inc. announced today that it has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus, which quickly raised concerns around the world because of the high number of mutations it carries, especially the 30-plus mutations on the Spike protein.
Influenza Vaccine Strains
ANTIGENS Seasonal flu is a common infectious disease of the respiratory tract caused by influenza virus. There are four types of influenza virus, influenza type A, B, C, and D. The A and B types are of most interest to the medical community because they are the culprits for seasonal epidemics. Occasionally, influenza A, like the A/California/04/09 (H1N1) and A/Hong Kong/1/1968 (H3N2), can even cause global pandemics.
CAR-T cells against cancer
Cancer immunotherapy exploits the body’s own immune system to fight against cancer. CAR-T cell therapy is one of the breakthrough approaches that involves re-engineering a patient’s own
T cells to recognize and eradicate cancer.
Deutsche Börse publishes BIOTECH Insight
Early December, Deutsche Börse has started BIOTECH Insight, a new information service on the German biotech industry.
US-Greek Venture gets €32m cash injection
US cell & gene therapy manufacturer Orgenesis Inc. announced that its joint venture with Theracell Advanced Biotechnology SA has received €32m in funding by Enterprise Greece.
The Digital Campus
Building on a relentless commitment to customer service and innovation, Beckman Coulter Life Sciences debuts a powerful new interactive customer resource with the launch of its Digital Campus. The 3D platform provides greater access to the company’s resources regardless of physical location and allows users to control their experience including the chance to get up close and personal with products and experts.
Early-stage ventures fighting AMR wanted!
The start-up competition @AMR conference supported by INCATE has started. Early-stage ventures fighting drug resistant bacterial infections in the therapeutics or diagnostics area interested to be on stage are invited to apply now!
EC signs prepurchase agreement with Valneva
The European Commission has inked the pre-purchase agreement over Valneva’s inactivated whole virus pandemic vaccine VLA2001 announed in mid-October.